SENISCA full BLACK-solid (002).png
SENISCA secures additional £3.7 million financing to support rapid development of senotherapeutic platform to treat age-related disease
March 18, 2024 03:00 ET | Senisca Ltd
SENISCA secures additional £3.7 million financing to support rapid development of senotherapeutic platform to treat age-related disease £3.7 million seed financing supported by consortium of new and...
MnM_logo_TM_JPG.JPG
RNA Therapeutics Market is Expected to Reach $18.0 billion | MarketsandMarkets.
October 02, 2023 08:30 ET | MarketsandMarkets Research Pvt. Ltd.
Chicago, Oct. 02, 2023 (GLOBE NEWSWIRE) -- The RNA therapeutics industry is poised for a transformative future as groundbreaking research and technological advancements continue to accelerate the...
SiSaf-Logo-1200-x-630-85.jpg
SiSaf Appoints Nikos Tzagkarakis in the New Role of Chief A.I. Officer
July 13, 2023 04:00 ET | SiSaf Ltd
GUILDFORD, England, July 13, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd announces that it has appointed Nikos Tzagkarakis in the newly created role of Chief A.I....
SiSaf-Logo-1200-x-630-85.jpg
FDA Grants SiSaf’s Innovative siRNA Therapy SIS-101-ADO Orphan Drug Designation and Rare Pediatric Disease Designation for the Treatment of Autosomal Dominant Osteopetrosis
May 15, 2023 03:00 ET | SiSaf Ltd
GUILDFORD, England, May 15, 2023 (GLOBE NEWSWIRE) -- SiSaf Ltd, an RNA delivery and therapeutics company, announces that SIS-101-ADO, its siRNA therapeutic for patients with Autosomal Dominant...
SiSaf-Logo-1200-x-630-85.jpg
SiSaf Appoints Dr. Richard Goodfellow to Board of Directors
April 05, 2023 03:00 ET | SiSaf Ltd
GUILDFORD, England, April 05, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd today announced that it has appointed Dr. Richard Goodfellow to its Board of Directors. ...
SiSaf-Logo-1200-x-630-85.jpg
SiSaf and the University of Leipzig Partner to Develop Bio-Courier Targeted miRNA for the Treatment of Pancreatic Cancer
March 02, 2023 04:00 ET | SiSaf Ltd
GUILDFORD, United Kingdom, March 02, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd today announces its collaboration with the University of Leipzig, Germany, to develop...
Roots-Analysis-Logo.png
The RNA targeting small molecule therapies market is projected to be worth around USD 8.3 billion in 2030, growing at an annualized rate of 35.26% during the period 2021-2030, claims Roots Analysis
March 23, 2022 12:55 ET | Roots Analysis
London, March 23, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “RNA Targeting Small Molecules Therapeutics Market, 2021-2030” report to its list of offerings. RNAs...
logo.gif
Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology
July 06, 2021 09:00 ET | Auris Medical AG
Treatment of KRAS-driven colorectal cancer selected as first therapeutic indication for OligoPhore™ platformCompany to launch development program under project code AM-401 with aim of IND submission...
logo.gif
Auris Medical Announces Significant Inhibition of Tumor Growth with OligoPhore siRNA Targeting NF-κB in Murine Model of Adult T-Cell Leukemia / Lymphoma
June 21, 2021 08:30 ET | Auris Medical AG
Treatment with OligoPhoreTM siRNA stops aggressive ATLL tumor growth to near zeroSignificant reduction in tumor size, spleen size and peripheral blood lymphocyte countsResults add to extensive body of...
mirecule logo.png
miRecule Inc. closes $5.7 M to Create Breakthrough RNA Therapies for Cancer and Muscular Dystrophy
May 27, 2021 11:07 ET | miRecule
GAITHERSBURG, Md., May 27, 2021 (GLOBE NEWSWIRE) -- miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced today it has...